Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.54 USD
Change Today -0.01 / -0.28%
Volume 63.4K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics inc (GALT) Snapshot

Open
$3.56
Previous Close
$3.55
Day High
$3.73
Day Low
$3.50
52 Week High
03/31/14 - $17.14
52 Week Low
12/24/14 - $3.00
Market Cap
83.4M
Average Volume 10 Days
130.6K
EPS TTM
--
Shares Outstanding
23.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALECTIN THERAPEUTICS INC (GALT)

galectin therapeutics inc (GALT) Related Bloomberg News

View More Bloomberg News

galectin therapeutics inc (GALT) Related Businessweek News

No Related Businessweek News Found

galectin therapeutics inc (GALT) Details

Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

7 Employees
Last Reported Date: 03/18/15
Founded in 2000

galectin therapeutics inc (GALT) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $569.7K
Executive Chairman
Total Annual Compensation: $360.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $127.3K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $260.0K
Compensation as of Fiscal Year 2013.

galectin therapeutics inc (GALT) Key Developments

Galectin Therapeutics, Inc. expected to report Fiscal Year 2014 results on March 27, 2015. This event was calculated by Capital IQ (Created on March 20, 2015).

Galectin Therapeutics, Inc. expected to report Fiscal Year 2014 results on March 27, 2015. This event was calculated by Capital IQ (Created on March 20, 2015).

Galectin Therapeutics, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Galectin Therapeutics, Inc. reported consolidated earnings results for the year ended December 31, 2014. The company reported fiscal year 2014 net loss applicable to common stockholders of $17.0 million, or $0.78 loss per basic and diluted share, compared with the prior year's $21.9 million, or $.30 loss per basic and diluted share. The company attributed the decrease in net loss applicable to common stockholders is largely due to an $8.8 million or $0.53 per share one-time, non-cash charge related to the modification of certain warrants recorded second quarter 2013 and an unrelated one-time, non-cash stock compensation charge of $1.0 million or $0.06 per share recorded in third quarter 2013, which were partially offset by increased research and development expenses primarily related to its clinical program. Total operating loss was $15.4 million against $12.1 million a year ago.

Galectin Therapeutics, Inc. announced delayed annual 10-K filing

On 03/16/2015, Galectin Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALT:US $3.54 USD -0.01

GALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALT.
View Industry Companies
 

Industry Analysis

GALT

Industry Average

Valuation GALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS INC, please visit www.galectintherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.